Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings

Management of the COVID-19 pandemic relies on molecular diagnostic methods supported by serological tools. Herein, we developed S-RBD- and N- based ELISA assays useful for infection rate surveillance as well as the follow-up of acquired protective immunity against SARS-CoV-2. ELISA assays were optim...

Descripción completa

Detalles Bibliográficos
Autores principales: Benabdessalem, Chaouki, Hamouda, Wafa Ben, Marzouki, Soumaya, Faye, Rokhaya, Mbow, Adji Astou, Diouf, Babacar, Ndiaye, Oumar, Dia, Ndongo, Faye, Ousmane, Sall, Amadou A., Diagne, Cheikh Tidiane, Amellal, Houda, Ezzikouri, Sayeh, Mioramalala, Diary Juliannie Ny, Randrianarisaona, Fanirisoa, Trabelsi, Khaled, Boumaiza, Mohamed, Hamouda, Sonia Ben, Ouni, Rym, Bchiri, Soumaya, Chaaban, Amani, Gdoura, Mariem, Gorgi, Yousr, Sfar, Imen, Yalaoui, Sadok, Khelil, Jalila Ben, Hamzaoui, Agnes, Abdallah, Meya, Cherif, Yosra, Petres, Stéphane, Mok, Chris Ka Pun, Escriou, Nicolas, Quesney, Sébastien, Dellagi, Koussay, Schoenhals, Matthieu, Sarih, M'hammed, Vigan-Womas, Inès, Bettaieb, Jihene, Rourou, Samia, Barbouche, Mohamed Ridha, Ahmed, Melika Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867841/
https://www.ncbi.nlm.nih.gov/pubmed/36805620
http://dx.doi.org/10.1016/j.diagmicrobio.2023.115903
Descripción
Sumario:Management of the COVID-19 pandemic relies on molecular diagnostic methods supported by serological tools. Herein, we developed S-RBD- and N- based ELISA assays useful for infection rate surveillance as well as the follow-up of acquired protective immunity against SARS-CoV-2. ELISA assays were optimized using COVID-19 Tunisian patients’ sera and prepandemic controls. Assays were further validated in 3 African countries with variable endemic settings. The receiver operating curve was used to evaluate the assay performances. The N- and S-RBD-based ELISA assays performances, in Tunisia, were very high (AUC: 0.966 and 0.98, respectively, p < 0.0001). Cross-validation analysis showed similar performances in different settings. Cross-reactivity, with malaria infection, against viral antigens, was noticed. In head-to-head comparisons with different commercial assays, the developed assays showed high agreement. This study demonstrates, the added value of the developed serological assays in low-income countries, particularly in ethnically diverse populations with variable exposure to local endemic infectious diseases.

Ejemplares similares